CICH2CH2
/CH2'CH'CO2H CICH CH 2 2 NH2 p-di-2-chloroethylamino-L-phenylalanine. Pharmacologically melphalan resembles nitrogen mustard, but it is wen absorbed when administered by.the oral route. The main toxic effects in man are similar to those of the other alkylating drugs; thus the lymphoid and haemopoietic system, and the gastro-intestinal tract, are particularly vulnerable. Melphalan is insoluble in water but can be dissolved in an ethyl alcohol/propylene glycol mixture. Its half life in blood at 37' C. is 105-120 minutes.
Phenylalanine occupies a central place in the synthesis of melanin and it might be expected that melphalan would exert a major inhibitory effect on melanoma ceRs and Luck (1956) reported inhibition of the Harding-Passey melanoma in a small number of mice treated with this drug. Holland and Regelson (1958) (1958) suggested that the clrug might be of some value in Hodgkin's disease. Recent work (Speed, D. E., 1963, personal communication) suggests that about one-third of myeloma patients 17 respond to melphalan; it has also been stated that response may occur in reticulum cell sarcoma, Kaposi's sarcoma, neuro and fibrosarcoma and seminoma. Creech, Ryan and Krementz (1959) have administered melphalan by isolation perfusion to patients with melanoma of the extremities.
Method of Therapy Melphalan was given orally. Twenty-seven patients received 2-0 to 3-0 mg./kg. over a 4-5 day period. Two cases (11, 12) received 10-0 mg./kg. over 4 days. After the initial treatment, maintenance therapy was given to four patients (I 1, 13, 14, Treatment.-The right antro-ethmoidal area was explored using a lateral approach. The tumour was found to invade extensively the right orbit, which was exenterated together with the right ethmoidal labyrinth and frontal sinus, removal was incomplete about the bony floor of the right anterior cranial fossa. Histologically the tumour was a melanotic melanoma. Melphalan therapy was instituted on the fifth post-operative day (DI) as 2-0 mg./kg. . Two further courses of melphalan 2-0 mg./kg. were administered from D40-44 and from D69-73. The relevant haematological findings are noted in Table I. Response.-By D16 there was an obvious decrease in the size of the tumour and the preauricular gland. Improvement continued up to and after the second course of melphalan. Biopsies were taken on D51 from areas previously known to be involved by tumour and these were histologically negative. The preauricular gland was no longer palpable. The third course of melphalan was given because of the nature of the ori-ainal -arowth. 
. (Fig. 1) (Fig. 3) Burkitt and O'Connor (1961) . This multifocal disease occurs in children. The characteristic clinical feature of 13 of the 14 cases reported here was involvement of one or more j'aw quadxants by a rapidly growing osteolytic tumour (Fig. 1) . This tumour responds to alkylating agents in a manner similar to most lymphomas. The points of difference are the initial great sensitivity (Fig. 2) , the early appearance of resistance, and the rapid progress of the disease. These points, together with the presence of an easily assessable jaw tumour, make this lymphoma a very sensitive test system for antitumour agents.
Fourteen cases (3-16) of this tumour synclrome were treated with melphalan. Tbxee cases (3, 11, 14) showed a marked regression, and improvement was slight in two cases (4, 16 (Oettgen, Clifford and Burkitt, 1962) (Clift, Wright and Clifford, 1963 Haematological.-Significant haematological toxicity was noted in three patients (11, 25, 27) and in two cases (25, 27) 
